AlfaSigma To Launch New Supplement Containing OptiBiotix Probiotic

Mon, 27th Jan 2020 09:50

(Alliance News) - OptiBiotix Health PLC on Monday said AlfaSigma SpA is launching a food supplement containing OptiBiotix's LPLDL probiotic strain.

Shares in supplements firm OptiBiotix were up 0.9% at 55.50 pence in London in morning trading.

The LPLDL probiotic strain of bacteria was developed by OptioBiotix's ProBiotix Health unit and is intended to reduce cholesterol. It will be included in the supplement, which AlfaSigma will market in Italy.

This follows the June 2018 announcement of an extended licence agreement between OptiBiotix and AlfaSigma "to exclusively commercialise food supplements containing OptiBiotix's cholesterol and blood pressure reducing LPLDL strain in Italy".

In 2018, AlfaSigma generated more than EUR1 billion in revenue. Italy is AlfaSigma's core market, though it is present in over 90 countries via subsidiaries and distributors

A marketing campaign targeting general practitioners, pharmacists and cardiologists, will take place. OptiBiotix noted that "Italy is the largest probiotic supplement market in Europe, and the second largest market in the world", with a probiotic supplements market of more than USD500 million likely to grow 25% per annum to 2021.

ProBiotix Health Chief Executive Stephen Prescott said: "We are pleased to communicate the launch of a new product developed by one of the largest pharmaceutical companies in Italy and containing our cholesterol reducing probiotic, LPLDL. Italy is the largest and fastest growing probiotic market in Europe and we are pleased to partner with a company with such a strong track record in food supplements and pharmaceuticals for cardiovascular health. The launch of this product is another step in establishing LPLDL as a global probiotic brand. This agreement is another step in building ProBiotix Health into a profitable business in 2020."

By Anna Farley; annafarley@alliancenews.com

OptiBiotix Health